Abstract
Recent investigations revealed microsatellite instability in colon cancers are associated with mutations of the transforming growth factor-β receptor type II gene (TGF-β RII) that encodes a transmembrane protein containing an intracellular serine/threonine kinase domain. Activation of TGF-β receptor type I (RI) and RII by TGF-β induces nuclear translocation of Smad proteins including Smad2 and Smad4 that have been originally identified as tumour suppressor genes. We have previously reported six cases with microsatellite instability in 32 oesophageal carcinomas. In this study, we analysed genetic mutations of TGF-β RII, Smad2 and Smad4 in these oesophageal carcinoma tissues and established 16 cell lines. No genetic mutation was detected in any tissues or cell lines except one tissue sample of microsatellite stable oesophageal carcinoma, that is, a mis-sense mutation of glutamic acid to glutamine at codon 526 (E526Q) in the TGF-β RII serine/threonine kinase domain. Interestingly, the mutant TGF-β RII E526Q can completely inhibit TGF-β-induction of nuclear translocation of Smad4 protein in oesophageal carcinoma cells. This mutation of TGF-β RII that is not associated with microsatellite instability might make a dominant negative effect on TGF-β signal transduction in oesophageal carcinoma. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
De M, Yan W, de Jonge RR, Garrigue-Antar L, Vellucci VF and Reiss M (1998) Functional characterization of transforming growth factor β type II receptor mutants in human cancer. Cancer Res 58: 1986–1992
Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL and Attisano L (1996) MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543–552
Fishel R (1998) Mismatch repair molecular switches and signal transduction. Genes Dev 12: 2096–2101
Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF and Reiss M (1995) Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 55: 3982–3987
Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK and Markowitz S (1999) Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 59: 320–324
Hata A, Shi Y and Massague J (1998) TGF-β signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today 4: 257–262
Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE (1996) DPC4 a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350–353
Kretzschmar M and Massague J (1998) SMADs: mediators and regulators of TGF-β signaling. Curr Opin Genet Dev 8: 103–111
Lengauer C, Kinzler KW and Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643–649
Markowitz S, Wang J, Myeroff L, Parsons R, Sun LZ. Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW and Vogelstein B (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336–1338
Massague J (1998) TGF-β signal transduction. Annu Rev Biochem 67: 753–791
Nakashima H, Mori M, Mimori K, Inoue H, Shibuta K, Baba K, Mafune K and Akiyoshi T (1995) Microsatellite instability in Japanese esophageal carcinoma. Int J Cancer 64: 286–289
Sugimachi K, Watanabe M, Sadanaga N, Ikebe M, Kitamura K, Mori M and Kuwano H (1994) Recent advances in the diagnosis and surgical treatment of patients with carcinoma of the esophagus. J Am Coll Surg 178: 363–368
Tanaka S and Wands JR (1996) Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor β-induced apoptosis. Cancer Res 56: 3391–3394
Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R and Sugimachi K (1993) Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 53: 2884–2887
Tanaka S, Akiyoshi T, Mori M, Wands JR and Sugimachi K (1998) A novel frizzled gene identified in human esophageal carcinoma that mediates APC/β-catenin signals. Proc Natl Acad Sci USA 95: 10164–10169
Wang J, Sun LZ, Myeroff L, Wang XF, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JKV and Brattain MG (1995) Demonstration that mutation of the type II transforming growth factor receptor β inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270: 22044–22049
Wrana JL, Attisano L, Wieser R, Ventura F and Massague J (1994) Mechanism of activation of the TGF-β receptor. Nature 370: 341–347
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Tanaka, S., Mori, M., Mafune, Ki. et al. A dominant negative mutation of transforming growth factor- β receptor type II gene in microsatellite stable oesophageal carcinoma. Br J Cancer 82, 1557–1560 (2000). https://doi.org/10.1054/bjoc.1999.1178
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1178